ArticleCEN case reports2026
ANCA-negative pauci-immune crescentic glomerulonephritis associated with nivolumab in lung cancer.
Article in CEN case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune checkpoint inhibitors (ICIs) have substantially improved the prognosis of many cancer patients but are also associated with various immune-related adverse events (irAEs). Kidney irAEs are relatively rare, with acute tubulointerstitial nephritis being the most common manifestation. However, some patients develop ICIs-associated glomerular diseases, including pauci-immune crescentic glomerulonephritis. In this report, we present the case of a 72-year-old man with lung squamous cell carcinoma treated with nivolumab, a monoclonal antibody targeting programmed cell death 1 (PD-1). The patient developed rapidly progressive glomerulonephritis a few weeks after initiating nivolumab therapy. Immunological tests yielded negative results, and a kidney biopsy revealed pauci-immune crescentic glomerulonephritis. Immunohistological examination confirmed programmed death ligand-1 (PD-L1) expression in the glomeruli. Despite intensive therapy, including corticosteroid pulse treatment, the patient's kidney function did not recover, necessitating maintenance hemodialysis. This is the first report demonstrating PD-L1 staining in injured glomeruli caused by anti-PD-1 therapy. Immunohistochemistry for PD-L1 may aid in diagnosing glomerulonephritis related to anti-PD-1 therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.